Kepos Capital LP Exelixis, Inc. Transaction History

Kepos Capital LP

$228 Million
Q3 2024

A detailed history of Kepos Capital LP transactions in Exelixis, Inc. stock. As of the latest transaction made, Kepos Capital LP holds 75,000 shares of EXEL stock, worth $2.67 Million. This represents 0.85% of its overall portfolio holdings.

Number of Shares

75,000

Previous 175,000 57.14%

Holding current value

$2.67 Million

Previous $3.93 Million 50.51%

% of portfolio

0.85%

Previous 1.53%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$21.96 - $27.6 $2.2 Million - $2.76 Million	-100,000 Reduced 57.14%	75,000 $1.95 Million
Q2 2024 Aug 13, 2024	BUY	$20.34 - $23.73 $2.24 Million - $2.61 Million	110,000 Added 169.23%	175,000 $3.93 Million
Q1 2024 May 10, 2024	BUY	$20.17 - $23.93 $1.31 Million - $1.56 Million	65,000 New	65,000 $1.55 Million
Q2 2023 Aug 10, 2023	BUY	$18.17 - $20.48 $4.54 Million - $5.12 Million	250,000 New	250,000 $4.78 Million
Q1 2020 May 12, 2020	SELL	$14.46 - $21.8 $918,585 - $1.38 Million	-63,526 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$15.15 - $18.89 $33,451 - $41,709	2,208 Added 3.6%	63,526 $1.12 Million
Q3 2019 Nov 13, 2019	SELL	$17.68 - $22.65 $1.39 Million - $1.78 Million	-78,542 Reduced 56.16%	61,318 $1.08 Million
Q2 2019 Aug 13, 2019	SELL	$18.93 - $24.75 $2.86 Million - $3.74 Million	-150,932 Reduced 51.9%	139,860 $2.99 Million
Q1 2019 May 13, 2019	BUY	$19.6 - $24.76 $2.74 Million - $3.47 Million	139,960 Added 92.79%	290,792 $6.92 Million
Q4 2018 Feb 13, 2019	BUY	$13.65 - $21.8 $1.48 Million - $2.36 Million	108,129 Added 253.21%	150,832 $2.97 Million
Q1 2018 May 14, 2018	BUY	$22.15 - $31.89 $945,871 - $1.36 Million	42,703 New	42,703 $946,000

Others Institutions Holding EXEL

# of Institutions

501

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kepos Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Kepos Capital LP with notifications on news.

Account